Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology > Antibiotics > Flashcards

Antibiotics Flashcards

Reinforce antibiotic classes, MOAs and Indications (261 cards)

Start Studying
1
Q

Penicillin G - Class

A

Penicillins - natural penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Penicillin G - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Penicillin G - Uses

A

Gram positive bacteria; without penicillinase resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Penicillin G - Specific targets

A 
Strep. Pneumoniae (bacterial pneumonia, meningitis)
Neisseria sp. (Gonorrhea)
Clostridium perfringens (Gas Gangrene)
Syphilis
Pharyngitis (β-heomlytic streptococcus)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Penicillin G - Resistance

A

All penicillinase

>90% of staph. aureus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Penicillin G -Pharmacokinetics

A

IV administered
t(1/2)=30 minutes
Renally excreted
Can be stabilized with Benzathine (4.1 day t1/2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Penicillin G - ADR

A 
Hypersensitivity
Diarrhea
Nephrotoxicity
Neurotoxicity
Hematologic toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Penicillin V - Class

A

Penicillins - natural penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Penicillin V - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Penicillin V - Uses

A

Gram positive bacteria; without penicillinase resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Penicillin V - Specific Targets

A 
Strep. Pneumoniae (bacterial pneumonia, meningitis)
Neisseria sp. (Gonorrhea)
Clostridium perfringens (Gas Gangrene)
Syphilis
Pharyngitis (β-heomlytic streptococcus)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Penicillin V - Resistance

A

All penicillinase

>90% of staph. aureus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Penicillin V - Pharmacokinetics

A

IV administered
t(1/2)=30 minutes
Renally excreted
Can be stabilized with Benzathine (4.1 day t1/2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Penicillin V - ADR

A 
Hypersensitivity
Diarrhea
Nephrotoxicity
Neurotoxicity
Hematologic toxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Methicillin - Class

A

Penicillinase-resistant (antistaphyoloccal) Penicillins

NO LONGER USED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nafcillin - Class

A

Penicillinase-resistant (antistaphyoloccal) Penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Oxacillin - Class

A

Penicillinase-resistant (antistaphyoloccal) Penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cloxacillin - Class

A

Penicillinase-resistant (antistaphyoloccal) Penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dicloxacillin - Class

A

Penicillinase-resistant (antistaphyoloccal) Penicillins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Nafcillin - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Ocacillin - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Cloxacillin - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Dicloxacillin - MOA

A

β-lactam; inhibits peptidoglycan formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Nafcillin - Uses

A

Restricted for S. Aureus strains expressing penicillinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Oxacillin - Uses
Restricted for S. Aureus strains expressing penicillinase
26
Cloxacillin - Uses
Restricted for S. Aureus strains expressing penicillinase
27
Dicloxacillin - Uses
Restricted for S. Aureus strains expressing penicillinase
28
Nafcillin - Target bacteria
β-lactamase producing staphylococci Penicillin susceptible streptococci & pneumococci Staphylococcal endocarditis
29
Oxacillin - Target bacteria
β-lactamase producing staphylococci Penicillin susceptible streptococci & pneumococci Staphylococcal endocarditis
30
Cloxacillin - Target bacteria
β-lactamase producing staphylococci | Penicillin susceptible streptococci & pneumococci
31
Dicloxacillin - Target bacteria
β-lactamase producing staphylococci Penicillin susceptible streptococci & pneumococci Mild to moderate staph infections
32
Nafcillin - Resistance
Altered PBP - found in MRSA; resistant to all class
33
Oxacillin - Resistance
Altered PBP - found in MRSA; resistant to all class
34
Cloxacillin - Resistance
Altered PBP - found in MRSA; resistant to all class
35
Dicloxacillin - Resistance
Altered PBP - found in MRSA; resistant to all class
36
Nafcillin - Pharmacokinetics
IV administered Short half-life Biliary excreted
37
Oxacillin - Pharmacokinetics
IV administered Short half-life Renally excreted
38
Cloxacillin - Pharmacokinetics
PO administered Short half-life Renally excreted
39
Dicloxacillin - Pharmacokinetics
PO administered Short half-life Renally excreted
40
Nafcillin - ADR
All penicillin ADRs plus Neutropenia Interstitial Nephritis
41
Oxacillin - ADR
All penicillin ADRs plus | Hepatitis
42
Cloxacillin - ADR
All penicillin ADRs
43
Dicloxacillin - ADR
All penicillin ADRs
44
Nafcillin specific ADRs
Neutropenia | Interstitial Nephritis
45
Oxacillin specific ADRs
Hepatitis
46
Ampicillin - Class
Extended spectrum penicillin
47
Amoxicillin - Class
Extended spectrum penicillin
48
Ampicillin - MOA
β-lactam; inhibits peptidoglycan formation
49
Amoxicillin - MOA
β-lactam; inhibits peptidoglycan formation
50
Ampicillin - Uses
Broad spectrum | Effective against some gram negative organisms
51
Amoxicillin - Uses
Broad spectrum | Effective against some gram negative organisms
52
Ampicillin - Targets
L. Monocytogenes | +/- aminoglycoside, gentamicin
53
Amoxicillin - Targets
Drug of choice for URTI Bacteria rhinosinusitis, otitis, & Lower RTI Dental prophylaxis in patients at risk of bacteria endocarditis
54
Ampicillin - Pharmacokinetics
IV administered
55
Amoxicillin - Pharmacokinetics
PO administered | Absorption not delayed by food
56
Ampicillin - Resistance
β-lactamases, coadminister sulbactam (IV) Some H. influenzas produce resistant PBPs No longer useful for UTIs or Typhoid fever
57
Amoxicillin - Resistance
β-lactamases, coadminister clavulanate (PO) | Some H. influenzas produce resistant PBPs
58
Piperacillin - Class
Extended spectrum penicillin (anti-pseudomonal)
59
Piperacillin - MOA
β-lactam; inhibits peptidoglycan formation
60
Piperacillin - Uses
Gram negative bacteria | Effective against pseudomonas
61
Piperacillin - Targets
Pseudomonas | Klebsiella pneumoniae
62
Piperacillin - Pharmacokinetics
IV/IM Coadminister with Tazobactam (Pip-Tazo) for extended coverage Renally eliminated
63
Piperacillin - Resistance
Covers penicillinase producing organisms when administered with tazobactam
64
Piperacillin - ADR
Coadministration with vancomycin causes increased risk of acute interstitial nephritis (DDI) Reduced coagulation with high dose (bleeding)
65
Amoxicillin - ADR
Penicillin ADRs
66
Ampicillin - ADR
Penicillin ADRs
67
Cafazolin - Class
First generation cephalosporin
68
Cephalexin - Class
First generation cephalosporin
69
Cefadroxil - Class
First generation cephalosporin
70
Cafazolin - MOA
β-lactam; inhibits peptidoglycan formation
71
Cephalexin - MOA
β-lactam; inhibits peptidoglycan formation
72
Cefadroxil - MOA
β-lactam; inhibits peptidoglycan formation
73
Cafazolin - Uses
Effective against MSSA Penicillinase-producing staphylococci Surgical prophylaxis
74
Cephalexin - Uses
Effective against MSSA | Penicillinase-producing staphylococci
75
Cefadroxil - Uses
Effective against MSSA | Penicillinase-producing staphylococci
76
Cafazolin - Targets/clinical uses
MSSA Streptococcal infections UTI Staph/strep soft tissue infection
77
Cephalexin - Targets/clinical uses
MSSA Streptococcal infections UTI Staph/strep soft tissue infection
78
Cefadroxil - Targets/clinical uses
MSSA Streptococcal infections UTI Staph/strep soft tissue infection
79
Cafazolin - Pharmacokinetics
IV Administration Penetrates most tissue, but not BBB Renally excreted
80
Cephalexin - Pharmacokinetics
PO Administration | Renally excreted
81
Cefadroxil - Pharmacokinetics
PO Administration | Renally excreted
82
Cafazolin - ADR
Cephalosporin ADRs
83
Cephalexin - ADR
Cephalosporin ADRs
84
Cefadroxil - ADR
Cephalosporin ADRs
85
Cephalosporin ADRs
``` Cross-reactivity with penicillins Some have anti-vitamin K effects Some cause disulfiram-like action (block EtOH oxidation) Injection site irritation Renal toxicity (rare) ```
86
Cefaclor - Class
Second generation cephalosporins
87
Cefuroxime - Class
Second generation cephalosporins
88
Cefprozil - Class
Second generation cephalosporins
89
Cefoxitin - Class
Second generation cephalosporins
90
Cefotetan - Class
Second generation cephalosporins
91
Cefaclor - Uses
Same as first generation with extended gram negative coverage
92
Cefuroxime - Uses
Same as first generation with extended gram negative coverage
93
Cefprozil - Uses
Same as first generation with extended gram negative coverage Poor against pseudomonas or enterococci
94
Cefoxitin - Uses
Same as first generation with extended gram negative coverage Poor against pseudomonas or enterococci
95
Cefotetan - Uses
Same as first generation with extended gram negative coverage Poor against pseudomonas or enterococci
96
Cefaclor - Targets
URTI | Soft tissue infections
97
Cefuroxime - Targets
URTI | Soft tissue infections
98
Cefoxitin - Targets
URTI Soft tissue infections Gynecologic infections Perioperative surgical prophylaxis
99
Cefotetan - Targets
Gynecologic infections | Perioperative surgical prophylaxis
100
Cefaclor - Pharmacokinetics
PO administered | Renally eliminated
101
Cefuroxime - Pharmacokinetics
PO administered | Renally eliminated
102
Cefoxitin - Pharmacokinetics
IV administered - AVOID IM Administration | Renally eliminated
103
Cefotetan - Pharmacokinetics
IV administered - AVOID IM Administration | Renally eliminated
104
Cefprozil - Pharmacokinetics
IV administered - AVOID IM Administration | Renally eliminated
105
Cefaclor - ADR
Cephalosporin ADRs
106
Cefuroxime - ADR
Cephalosporin ADRs
107
Cefoxitin - ADR
Cephalosporin ADRs | Painful if injected IM
108
Cefotetan - ADR
Cephalosporin ADRs | Painful if injected IM
109
Cefprozil - ADR
Cephalosporin ADRs | Painful if injected IM
110
Cefotaxime - Class
Third Generation Cephalosporin
111
Ceftazidime - Class
Third Generation Cephalosporin
112
Ceftriaxone - Class
Third Generation Cephalosporin
113
Cefdinir - Class
Third Generation Cephalosporin
114
Cefpodoxime - Class
Third Generation Cephalosporin
115
Cefotaxime - Uses
Mostly gram negative activity Less potent against gram positive Treats resistant infections
116
Ceftazidime - Uses
Mostly gram negative activity Less potent against gram positive Treats resistant infections Effective against psuedomonas
117
Ceftriaxone - Uses
Mostly gram negative activity Less potent against gram positive Treats resistant infections
118
Cefdinir - Uses
Mostly gram negative activity Less potent against gram positive Treats resistant infections
119
Cefpodoxime - Uses
Mostly gram negative activity Less potent against gram positive Treats resistant infections
120
Cefotaxime - Targets
``` Gonorrhea CAP Meningitis UTI Streptococcal endocarditis Severe Lyme ```
121
Ceftazidime - Targets
HAP Meningitis TUI Intra-abdominal infection
122
Ceftriaxone - Targets
``` Gonorrhea CAP Meningitis UTI Streptococcal endocarditis Severe Lyme ```
123
Cefdinir - Targets
``` Gonorrhea CAP Meningitis UTI Streptococcal endocarditis Severe Lyme ```
124
Cefpodoxime - Targets
``` Gonorrhea CAP Meningitis UTI Streptococcal endocarditis Severe Lyme ```
125
Cefotaxime - Pharmacokinetics
IV/IM Administered Penetrate body fluids well (inc. CSF) Renally excreted
126
Ceftazidime - Pharmacokinetics
IV/IM Administered | Renally excreted
127
Ceftriaxone - Pharmacokinetics
IV/IM Administered Penetrate body fluids well (inc. CSF) Biliary Excretion
128
Cefdinir - Pharmacokinetics
PO administered | Renally excreted
129
Cefpodoxime - Pharmacokinetics
PO Administered | Renally excreted
130
Cefepime - Class
Fourth generation cephalosporin
131
Cefotaxime - ADR
Cephalosporin ADRs
132
Ceftazidime - ADR
Cephalosporin ADRs
133
Ceftriaxone - ADR
Cephalosporin ADRs
134
Cefdinir - ADR
Cephalosporin ADRs
135
Cefpodoxime - ADR
Cephalosporin ADRs
136
Cefepime - Uses
Third generation cephalosporin plus pseudomonas and multi-drug resistant strains
137
Cefepime - Target
Enterobacter Pseudomonas Most penicillin-resistant strains of streptococci
138
Cefepime - Pharmacokinetics
IV administered Distributes well in CSF Renally cleared
139
Cefepime - Clinical uses
``` CAP Gonorrhea Meningitis UTI Streptococcal endocarditis ```
140
Cefepime - ADR
Cephalosporin ADRs
141
Ceftraroline - Class
Anti-MRSA cephalosporin
142
Ceftraroline - Uses
Reserved for use with MRSA
143
Ceftraroline - MOA
Binds mutated PBP that confers resistance to other | β-lactams
144
Ceftraroline - Pharmacokinetics
IV Admimistered Renally excreted T1/2 = 2.7 hours
145
Ceftraroline - ADR
Cephalosporin ADRs
146
Aztreonam - Class
Monobactam
147
Aztreonam - MOA
β-lactam; inhibits peptidoglycan formation
148
Aztreonam - Uses
Gram negative only
149
Aztreonam - Targets
Aerobic gram negative bacteria | including pseudomonas
150
Aztreonam - Pharmacokinetics
IV Administered Penetrates BBB Renally cleared
151
Aztreonam - ADRs
Skin rashes Elevation of serum aminotransferase **Safe for patients with penicillin allergy
152
Imipenem - Class
Carbapenem
153
Doripenem - Class
Carbapenem
154
Ertapenem - Class
Carbapenem
155
Meropenem - Class
Carbapenem
156
Imipenem - MOA
β-lactam; inhibits peptidoglycan formation
157
Doripenem - MOA
β-lactam; inhibits peptidoglycan formation
158
Ertapenem - MOA
β-lactam; inhibits peptidoglycan formation
159
Meropenem - MOA
β-lactam; inhibits peptidoglycan formation
160
Imipenem - Uses
Broad spectrum | Empiric Treatment
161
Doripenem - Uses
Broad spectrum | Empiric Treatment
162
Ertapenem - Uses
Broad spectrum | Empiric Treatment
163
Meropenem - Uses
Broad spectrum | Empiric Treatment
164
Imipenem - Pharmacokinetics
IV Administered MUST coadminister cilastatin Renally cleared Hydrolyzed to toxic metabolite - inhibited by cilastatin
165
Doripenem - Pharmacokinetics
IV Administered | Renally cleared
166
Ertapenem - Pharmacokinetics
IV Administered | Renally cleared
167
Meropenem - Pharmacokinetics
IV Administered | Renally cleared
168
Imipenem - ADR
N/V/D Seizures Cross-reactive with penicillin hypersensitivity
169
Doripenem - ADR
N/V/D Seizures Cross-reactive with penicillin hypersensitivity
170
Ertapenem - ADR
N/V/D Seizures Cross-reactive with penicillin hypersensitivity
171
Meropenem - ADR
N/V/D Seizures Cross-reactive with penicillin hypersensitivity
172
Vancomycin - Class
Glycopeptides
173
Dalbavancin - Class
Glycopeptides
174
Oritavancin - Class
Glycopeptides
175
Teicoplanin - Class
Glycopeptides
176
Telavancin - Class
Glycopeptides
177
Glycopeptides - MOA
Inhibit cell wall synthesis by preventing polymerization into glycan strands
178
Glycopeptides - Use
Gram positive and some anaerobes
179
Glycopeptides - Clinical Targets
Skin/soft tissue Infective endocarditis HAP
180
Glycopeptides - Pharmacokinetics
IV administered for systemic PO administered for Enteric infection (c. diff) Renally excreted
181
Glycopeptide - ADR
Phlebitis at injection site Ototoxicity - dose related Nephrotoxicity Histamine-mediated "red man" syndrome
182
Daptomycin - Class
Lipopeptides
183
Lipopeptides - MOA
Insert into plasma membrane and disrupt cell wall
184
Lipopeptides - Uses
Gram positive bacteria | Vancomycin resistant bacteria
185
Lipopeptide - Clinical Targets
NOT effective in pulmonary surfactant Skin/soft tissue infections Bacteremia Endocarditis
186
Lipopeptide - Pharmacokinetics
IV Administered | Renally cleared
187
Lipopeptide - ADR
Myopathy | Allergic Pneumonitis
188
Fosfomycin - MOA
Inhibits synthesis of muramic monomer | Transports into cell using glucose transporter
189
Fosfomycin - Uses
Uncomplicated UTI
190
Fosfomycin - Pharmacokinetics
PO administered | Excreted by kidney
191
Fosfomycin - ADR
N/V/D Vaginitis Headache
192
Amikacin
Aminoglycoside
193
Neomycin
Aminoglycoside
194
Gentamicin
Aminoglycoside
195
Streptomycin
Aminoglycoside
196
Tobramycin
Aminoglycoside
197
Aminoglycosides - MOA
Bind 30S subunit causing misreading of mRNA
198
Aminoglycosides - Uses
Broad spectrum, serious infections | Use synergistically with β-lactam for broader spectrum
199
Aminoglycosides - Clinical
``` HAP Cystic fibrosis (pseudomonas) Peritonitis Endocarditis Sepsis Tularemia Plague ```
200
Aminoglycosides - ADR
``` Neomycin only topical to avoid nephrotoxicity Ototoxicity Nephrotoxicity Neurotoxicity Allergic reactions - to topical neomycin ``` Block presynaptic ACh release - no MG or NMJ blockers
201
Aminoglycosides - Pharmacokinetics
``` IV/IM Administration Intrathecal for CSF Poorly absorbed from GI tract Cross placental barrier Excreted unchanged in urine (good for UTI) ```
202
Doxycycline
Tertracycline
203
Tigecycline
Tertracycline
204
Minocycline
Tertracycline
205
Tertracycline
Tertracycline
206
Tertracyclines - MOA
Bind reversibly to 30S subunit, prevents tRNA binding Accumulates in cells via energy dependent transport
207
Tertracyclines - Uses
Broad spectrum gram positive | Tigecycline good against MRSA
208
Tertracyclines - Resistance
Efflux pumps Block Tertracycline binding Enzymatic inactivation
209
Tertracyclines - Clinical uses
``` MSSA & MRSA H. Pylori (Peptic ulcers) Lyme disease/Rocky Mountain spotted fever Cholera CAP Acne Chlamydia ```
210
Tertracyclines - Pharmacokinetics
``` PO (except doxycycline) Some remains in gut lumen Food impairs absorption (divalent chelation) Bound by serum proteins Hepatically metabolized Eliminated through feces and urine ```
211
Tertracyclines - ADR
``` Hypersensitivity reactions N/V/D Slowed bone growth/teeth discoloration (Ca++ chelation) Hepatotoxicity Nephrotoxocity Phototoxicity Dizziness, vertigo, tinnitus ```
212
Azithromycin
Macrolides
213
Clarithromycin
Macrolides
214
Erythromycin
Macrolides
215
Telithromycin
Macrolides
216
Macrolides - MOA
Bacteriostatic | Binds reversibly to 50S inhibiting peptide translocation
217
Macrolides - Uses
Broad spectrum agents | Many organisms susceptible to penicillin G - Erythromycin
218
Macrolides - Clinical
``` Pneumonia Mycoplasma Legionnaires Chlamida Diphteria Pertussis ```
219
Macrolides - Resistance
Inability to take up antibiotic Efflux pumps Decreased affinity of 50S subunity Enzymatic degredation
220
Macrolides - Pharmacokinetics
Well absorbed orally Erythromycin & azithromycin are in IV formulation Food interferes with absorption of erythromycin & azithromycin Widely distributed (no CSF) Diffuses into prostatic fluid Metabolized by CYP3A4 Biliary & renal excretion
221
Macrolides - ADR
``` Gastric distress Hepatotoxicity Ototoxicity Cardiotoxicity Hypersensitivity (Eryrthromycin) ```
222
Quinupristin/Dalfopristin - class
Streptogramins
223
Streptogramins - MOA
Bactericidal | Bind 50S subunit synergistically - prevent elongation, and disrupt elongation
224
Streptogramins - Uses
Gram positive cocci and enterococcus Reserved for severe VRE Treat atypical pneumonia
225
Streptogramins - Resistance
Efflux pumps | Enzymatic degredation
226
Streptogramins - Pharmacokinetics
IV administered No CSF Hepatically metabolized, fecal excretion CYP3A4 metabolism
227
Streptogramins - ADR
Phlebitis Hyperbilirubinemia in ~25% of patients Arthralgia and myalgia
228
Linezolid - Class
Oxazolidinones
229
Oxazolidinones - Uses
Bacteriostatic against aerobic gram positive organisms | Approved for Vancomycin resistant infections
230
Oxazolidinones - MOA
Bind 23S rRNA of 50S subunit. Prevents complexing
231
Oxazolidinones - Targets
VRE Mycobacterium tuberculosis MRSA - not first line
232
Oxazolidinones - Resistance
Reduced binding at target site
233
Oxazolidinones - Pharmacokinetics
PO or IV administration Oxidation into inactive metabolites Excreted renally/biliary
234
Oxazolidinones - ADR
``` N/V/D Headache Rash Thrombocytopenia Neurotoxicity - blindness with extended duration DDI - Serotonin syndrome ```
235
Chloramphenicol
Removed from US market. Major toxicity. Orally absorbed penetrates CSF and is inactivated by liver Gray baby syndrome
236
Clindamycin - Class
Lincosamides
237
Lincosamides - MOA
Bacteriostatic | Binds 50S subunit inhibiting translocation
238
Lincosamides - Uses
Gram positive organisms | Empiric for non severe infections of skin/oral cavity
239
Lincosamides - Targets
MRSA Strep Anaerobic bacteria
240
Lincosamides - Resistance
Inability to take up antibiotic Efflux pumps Decreased affinity of 50S subunity Enzymatic degredation
241
Lincosamides - Clinical
Skin/Soft tissue infection Infection of oral cavity Acne Intra-abdominal infection
242
Lincosamides - pharmacokinetics
IV (PO prodrug for pediatric use) Widely distributed in many tissues, no CSF >90% plasma bound Inactivated by hepatic metabolism
243
Lincosamides - ADR
Rash Stevens-Johnson syndrome (rare) N/V/D Risk of C. diff superinfection
244
Ciprofloxacin - Class
Fluoroquinolones
245
Levofloxacin - Class
Fluoroquinolones
246
Moxifloxacin - Class
Fluoroquinolones
247
Fluoroquinolones - MOA
Bactericidal | Bacteria DNA gyrase/topoisomerase inhibitor
248
Fluoroquinolones - Uses
Broad spectrum
249
Fluoroquinolones - Resistance
Efflux Enzymatic degredation altered gyrase/topoisomerase Reduced uptake
250
Fluoroquinolones - Targets
``` Anthrax UTI Anaerobic infection Resistant respiratory infection GI infection ```
251
Fluoroquinolones - Pharmacokinetics
``` PO administered (90% absorbed) Divalent metals impair absorption Plasma bound (varies) Distribute well throughout (+CSF) Eliminated renally ```
252
Fluoroquinolones - ADR
``` Tendonitis/Tendon ruputre CNS effects Phototoxicity Arthropathy Hepatotoxicity Cardiotoxicity Ciprofloxacin inhibits CYP4501A2 & 3A4 ```
253
Fluoroquinolones - DDI
Theophylline (asthma) Warfarin Tizanidine
254
Cotrimoxazole - Class
Folate Antagonist
255
Sulfamethoxazole/Trimethoprim - Class
Folate Antagonist
256
Folate Antagonist - MOA
Inhibit folic acid synthesis, some competitively with sulfa drugs
257
Folate Antagonist - Pharmacokinetics
PO administered - sulfasalazine not well absorbed orally IV reserved for severe patients Bind to serum albumin and distribute widely (+CSF) Renally excreted
258
Folate Antagonist - ADR
Crystalluria (sulfa drugs) Hypersensitivity (sulfa) Hematopoietic disturbance (sulfa) Kernicterus (Sulfa)- newborns
259
Folate Antagonist - DDI
Inhibits CYP2C9 Warfarin Phenytoin
260
Folate Antagonist - Spectrum
Broad, bacteriostatic
261
Folate Antagonist - Targets
``` MRS Respiratory infections Listeriosis Prostate/UTI GI infections ```

Pharmacology (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions